Fluid-filled intragastric balloons are an effective and safe weight loss option across BMI and age ranges

Author(s):  
Ricardo J. Marrero Torres ◽  
Federico Gregory ◽  
Carlos G. Micames
2011 ◽  
Vol 21 (10) ◽  
pp. 1499-1507 ◽  
Author(s):  
Evzen Machytka ◽  
Pavel Klvana ◽  
Asher Kornbluth ◽  
Steven Peikin ◽  
Lisbeth E. M. Mathus-Vliegen ◽  
...  

2021 ◽  
pp. 000313482110385
Author(s):  
Amit Mehta ◽  
Shawn Shah ◽  
Enad Dawod ◽  
Kaveh Hajifathalian ◽  
Rekha Kumar ◽  
...  

Background We conducted this study to compare the weight loss outcome of intragastric balloons (IGBs) in conjunction with pharmacotherapy vs IGB and intensive lifestyle changes alone. Methods This was a multicenter, non-randomized, retrospective study involving 4 academic hospitals. Patients underwent IGB placement with or without concomitant anti-obesity pharmacotherapy. The primary outcome was percent total weight loss (TBWL) after IGB placement at 6 and 12 months. Results This study included 102 patients, with 23 patients (mean age 46.6 years, 82.6% female) treated with IGB/pharmacotherapy and 79 patients (mean age 46.0 years, 88.6% female) treated with IGB/lifestyle modifications. Patients had a 100% follow-up rate at 6 and 12 months. At 6 months following IGB placement, both groups achieved a similar %TBWL. At 12 months, %TBWL was greater in the IGB/pharmacotherapy group (12.6% ± 1.2 vs 9.7% ± 0.7, P = .04). 65.2% of patients achieved ≥10% TBWL at 12 months in the IGB/pharmacotherapy group, compared to 38.0% in the IGB/lifestyle group ( P < .05). The proportion of patients that achieved ≥15% weight loss at 12 months was also significantly different between the IGB/pharmacotherapy and IGB/lifestyle groups (30.4% vs 20.3%, P < .05). Discussion IGB with concomitant use of pharmacotherapy did not improve weight loss while the IGB was in place compared to IGB and lifestyle changes. However, patients receiving IGB with pharmacotherapy did have greater weight loss and diminished weight regain after balloon removal compared to those receiving just IGB and lifestyle changes.


Appetite ◽  
2015 ◽  
Vol 89 ◽  
pp. 305
Author(s):  
L.J. Reece ◽  
P. Sachdev ◽  
R.J. Copeland ◽  
M. Thomson ◽  
J.K. Wales ◽  
...  

2020 ◽  
Vol 91 (6) ◽  
pp. AB227
Author(s):  
Sindhura Kolli ◽  
Gabrielle Maranga ◽  
Christine Ren-Fielding ◽  
Holly F. Lofton

Author(s):  
ALANA COSTA BORGES ◽  
PAULO CÉSAR ALMEIDA ◽  
STELLA M. T. FURLANI ◽  
MARCELO DE SOUSA CURY ◽  
SHANTANU GAUR

ABSTRACT Objective: to assess the short-term efficacy, tolerance and complications in high-risk morbidly obese patients treated with an intragastric balloon as a bridge for surgery. Methods: we conducted a post-hoc analysis study in a Brazilian teaching hospital from 2010 to 2014, with 23 adult patients with a BMI of 48kg/m2, who received a single intragastric air or liquid balloon. We defined efficacy as 10% excess weight loss, and complications, as adverse events consequent to the intragastric balloon diagnosed after the initial accommodative period. We expressed the anthropometric results as means ± standard deviation, comparing the groups with paired T / Student’s T tests, when appropriate, with p<0.05 considered statistically significant. Results: the balloons were effective in 91.3% of the patients, remained in situ for an average of 5.5 months and most of them (65.2%) were air-filled, with a mean excess weight loss of 23.7kg±9.7 (excess weight loss 21.7%±8.9) and mean BMI reduction of 8.3kg/m2±3.3. Complications (17.3%) included abdominal discomfort, balloon deflation and late intolerance, without severe cases. Most of the participants (82.7%) did not experience adverse effects. We removed the intragastric balloons in time, without intercurrences, and 52.2% of these patients underwent bariatric surgery within one month. Conclusion: in our center, intragastric balloons can be successfully used as an initial weight loss procedure, with good tolerance and acceptable complications rates.


2016 ◽  
Vol 83 (5) ◽  
pp. AB425-AB426
Author(s):  
Violeta Popov ◽  
Allison Schulman ◽  
Christopher C. Thompson

Sign in / Sign up

Export Citation Format

Share Document